DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cbc8lj/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Amorsa Therapeutics Inc.
- Edgemont Pharmaceuticals, LLC
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- MarcoPolo Pharmaceuticals SA
- Otsuka Holdings Co., Ltd.
- (dextromethorphan hydrobromide + quinidine sulfate)
- esketamine hydrochloride
- EVT-100 Series
- Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders
- Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders
For more information visit http://www.researchandmarkets.com/research/cbc8lj/treatment